INTRODUCTION
============

In the prostate-specific antigen (PSA) era, prostate cancer (PCa) screening in males has led to an increase in the identification of PCa patients with low-stage and low-grade disease \[[@B1]\]. However, PSA is unable to distinguish between clinically significant and nonsignificant PCa \[[@B2]\], raising concerns about its overtreatment \[[@B3]\]. Considerable investigations have aimed to overcome the limitations of PSA \[[@B4]\]. Recent studies have shown that \[−2\]proPSA (p2PSA) and its derivatives, percentage of p2PSA to free PSA (%p2PSA; \[(p2PSA pg/mL)/(free PSA ng/mL×1,000)\]×100) and the prostate health index (PHI; \[p2PSA/free PSA\]×√tPSA) (Beckman Coulter, La Brea, CA, USA) are related to PCa aggressiveness at biopsy \[[@B5]\] and contribute to improving the accuracy of total PSA (tPSA) and percentage of free PSA (%fPSA) for predicting the presence of PCa at prostate biopsy \[[@B6]\].

The predictive accuracy of PHI and %p2PSA with pathologic aggressiveness in PCa patients who underwent radical prostatectomy (RP) has mainly been reported in Western studies \[[@B7][@B8][@B9][@B10]\]. Higher PHI and %p2PSA levels predicted pT3 disease, higher pathologic Gleason sum (GS), and GS upgrading \[[@B10][@B11]\]. A few recent Asian studies involving Chinese males reported on the predictive accuracy of PHI and %p2PSA; the results were superior to those of Western studies \[[@B12][@B13]\].

The incidence of PCa increased in all areas of Asia between 2008 and 2012 \[[@B14][@B15]\]. However, the incidence and mortality differed significantly across Asia. The PCa mortality rate in the Taiwanese population increased between 1995 and 2006 \[[@B16][@B17]\], increased in the Korean population between 1983 and 2006 \[[@B18]\], and decreased in Singapore between 1998 and 2006 \[[@B19]\]. The PCa mortality rate in Japan remained stable from 2004 to 2013 \[[@B16][@B20]\]. The PCa epidemiology in South Korea differed from those of other Asian nations, probably because Korean males have different environmental and genetic factors than other Asian males \[[@B16]\].

In our previous prospective multicenter observational study, we reported that preoperative serum PHI and %p2PSA levels were more valuable than serum tPSA or %fPSA levels for predicting the presence of PCa in 246 Korean males who underwent prostate biopsy \[[@B21]\].

Here we evaluated the performance of PHI and %p2PSA for predicting final pathological outcomes of RP in Korean males.

MATERIALS AND METHODS
=====================

This prospective observational multicenter study included four institutions to evaluate the clinical utility of PHI and %p2PSA versus the existing biomarkers tPSA and %fPSA \[[@B21]\].

The study population included 160 consecutive patients who underwent RP for 12-core biopsy-proven PCa between June 2015 and August 2018. Exclusion criteria were a prior history of neoadjuvant androgen-deprivation therapy, use of 5α-reductase inhibitors, and conditions that could change the serum p2PSA concentration \[[@B21]\].

Blood samples of the enrolled patients were drawn at least 6 weeks from a prostate biopsy and prior to any manipulations that may cause a transient increase in serum biomarker concentrations. The blood samples were processed and managed as described in our previous study \[[@B21]\]. At a single laboratory, the serum samples were analyzed. Experienced genitourinary pathologists evaluated the RP specimens according to the Stanford protocol \[[@B22]\] and rated PCa grade according to the 2005 International Society of Urological Pathology consensus \[[@B23]\].

The primary end point of the present study was the clinical utility of preoperative PHI for predicting postoperative pathological outcomes of PCa. We assessed the presence of pT3, pathologic GS ≥7 PCa, and GS upgrading. PHI and %p2PSA were considered the index tests and compared with the established serum biomarkers tPSA, fPSA, and %fPSA.

Uni- and multivariate logistic regression models were employed to predict the presence of pT3, pathologic GS ≥7 PCa, and GS upgrading. The factors showing significant results in the univariate analysis were selected as covariates in the multivariate logistic regression models. We plotted the receiver operating characteristic (ROC) and used the area under the ROC curve (AUC) to quantify the predictive accuracy. Each of the variables (%p2PSA, PHI) was included in the base multivariate model including tPSA, %fPSA, PSA density, percentage of positive biopsy core, biopsy GS, and clinical stage to assess their ability to determine the three outcomes of interest. We quantified the predictive accuracy gain and used the DeLong method to compare the AUC values \[[@B24]\]. Decision-curve analysis (DCA) was used to evaluate whether the incorporation of %p2PSA and PHI levels into the base models improved the prognostic model utility \[[@B25]\]. The data of our cohort were analyzed using IBM SPSS Statistics version 25.0 (IBM Corp., Armonk, NY, USA) and R version 3.6.0 for Windows.

The present study protocol was reviewed and approved by the Institutional Review Board of Kangwon National University Hospital (approval number: KNUH 2015-04-004-001). Informed consent was obtained from all enrolled subjects.

RESULTS
=======

At the four different institutions, 160 patients were enrolled. [Table 1](#T1){ref-type="table"} shows the demographic and clinical characteristics of the enrolled patients. The median patient age was 69.7 years (range, 45--79 years). The median PSA level was 7.7 ng/mL (range, 3.5--74.9 ng/mL). Overall, 81 patients (50.6%) were diagnosed with pT3, 96 (60.0%) were diagnosed with pathologic GS ≥7, and 34 (21.3%) showed GS upgrading, which was defined as pathologic GS ≥7 from biopsy GS=6.

[Fig. 1](#F1){ref-type="fig"} shows that patients with pT3 stage, pathologic GS ≥7, and GS upgrading had significantly higher serum %p2PSA and PHI levels (all p\<0.001).

Clinical stage (cT1c vs. cT2), percentage of positive biopsy core, biopsy GS, PSA density, tPSA, and %fPSA were significant predictors of the probability of pT3 at pathologic staging on univariate analysis; these factors were selected as covariates in the base model of the multivariate logistic regression analysis ([Table 2](#T2){ref-type="table"}). Clinical stage, percentage of positive biopsy core, tPSA, and %fPSA were significant predictors of the probability of pathologic GS ≥7 and GS upgrading on univariate analysis; these factors were selected as covariates in the base models of the multivariate logistic regression analysis ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). The uni- and multivariate logistic regression models predicting the probability of pT3 disease ([Table 2](#T2){ref-type="table"}), pathologic GS ≥7 ([Table 3](#T3){ref-type="table"}), and GS upgrading ([Table 4](#T4){ref-type="table"}) revealed %p2PSA and PHI as independent variables (all p\<0.001). The inclusion of PHI or %p2PSA in the multivariate analyses significantly improved the predictive accuracy of the basic multivariate models. The increase in predictive accuracy was 4.0% to 13.1%. The ROC curves of these variables are shown in [Fig. 2](#F2){ref-type="fig"}.

[Fig. 3](#F3){ref-type="fig"} represents the plots of DCA for the models shown in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}. Models including PHI clearly resulted in a greater net benefit in pathologic outcome prediction. Net clinical benefit was observed by employing PHI and %p2PSA to predict pT3, pathologic GS ≥7, or GS upgrading at a threshold probability of 30% to 70%.

[Table 5](#T5){ref-type="table"} shows the sensitivity and specificity at three PHI levels for predicting pT3, pathologic GS ≥7, and GS upgrading. The best cut-off values of PHI for predicting pT3, pathologic GS, or GS upgrading were 45.55, 45.55, and 45.92, respectively.

DISCUSSION
==========

The current study shows the benefit of employing PHI and %p2PSA as preoperative factors for predicting the RP pathological results (pT3, pathologic GS ≥7, or GS upgrading) in cases of localized PCa patients in Korea. The inclusion of PHI and %p2PSA in multivariate models increased the predictive accuracy from 4.0% to 13.1%; the models including PHI in DCA exhibited greater net benefit with regard to pathologic outcome probability. DCA is a statistical tool that shows the net benefit of various models known to help predict the outcome in response to the probability of clinical outcome. Clinicians use DCA to determine which model to use to predict clinical outcomes. According to [Fig. 3A](#F3){ref-type="fig"}, for example, clinicians in a region with a T3 probability of 20% to 80% after prostatectomy can confirm that applying model 2 or 3 can better predict the probability of T3 than model 1. Our study demonstrated more strong positive results than those of previously reported studies.

Several European reports describe the relationship of PHI, a new biomarker, and RP pathological outcomes. Guazzoni et al. \[[@B11]\] first reported PHI and %p2PSA as more accurate predictors of PCa pathological outcomes than previously available markers predicting aggressive PCa in Italian males. However, the gain in predictive accuracy in their study was lower than our study results, and the models including %p2PSA and PHI showed no benefit in pT3 prediction in their DCA \[[@B11]\]. Fossati et al. \[[@B10]\] also confirmed %p2PSA and PHI as significant predictors of pT3 disease and/or pathologic GS ≥7 versus other predictive factors such as PSA, DRE, biopsy, GS, and percentage of positive cores in a multicenter European study of 489 consecutive PCa patients. However, their DCA showed no benefit in pT3 and pathologic GS ≥7 prediction and negative results \[[@B10]\]. Eminaga et al. \[[@B9]\] reported that PHI was not an independent predictor of RP pathological outcomes in German PCa patients in a multivariate analysis.

A few Asian studies have demonstrated the relationship between PHI and pathologic outcome after RP. Chiu et al. \[[@B26]\] reported that both PHI and %p2PSA predict aggressive RP pathological outcomes in Chinese males; the study results showed an improved AUC and a net benefit in DCA; however, the gain in predictive accuracy was lower than that of the present study.

To the best of our knowledge, here we demonstrated for the first time in the literature the strong relationship between %p2PSA, PHI, and aggressive RP pathological outcomes in a Korean cohort. The predictive performance of PHI and %p2PSA of our study was superior to that of the Chinese and European cohort \[[@B11][@B26][@B27]\]. In the DCA of PHI of our study, a net clinical benefit was seen for pT3, pathologic GS ≥7, and GSn upgrading, and the result was similar to that of a Chinese report \[[@B26]\]. However, the DCA in the two European studies showed no significant net clinical benefit \[[@B10][@B11]\]. The two European cohorts showed much higher proportions (up to 70%) of patients with clinically aggressive disease (pT3 or pathologic GS ≥7) and lower median PSA levels than our cohort \[[@B10][@B11]\]. We postulated that the performance difference of PHI or %p2PSA between Westerners and Asian Chinese and Koreans might be due to differences in PCa epidemiology (incidence and aggressiveness) and ethnicity. The higher percentage of GS upgrading (32.5%) compared to other studies may have contributed to the superior PHI performance in our studies.

Our previous study demonstrated that PHI and %p2PSA were more valuable biomarkers for predicting the presence of PCa at prostate biopsy than were tPSA and %fPSA \[[@B21]\]. In the subgroup analysis, these two biomarkers showed superior performance for predicting a GS ≥7 in PCa patients \[[@B21]\]. This result was similar to those of Western and other Asian reports. As a follow-up study, we statistically analyzed the final pathological findings after RP and the relationship with these two biomarkers PHI and %p2PSA. In particular, we demonstrated the superior clinical utility of PHI for predicting the probability of GS upgrading, which is one of the biggest concerns when applying active surveillance therapy to the treatment of early PCa. PHI can be a useful clinical biomarker for selecting PCa patients who are subject to active surveillance therapy. We are working on a study to prove this hypothesis.

The strengths of the current study include the following: its prospective observational study, blood processing based on recommended protocol \[[@B28]\], analyses of prostatectomy pathologic findings, and use of DCA \[[@B25]\]. The limitations of the current study include a lack of tumor volume analysis, lack of preoperative MRI finding analysis such as Prostate Imaging Reporting and Data System score, and relatively small sample size. The minimum number of subjects to ensure adequate study power was 150 \[[@B29]\].

CONCLUSIONS
===========

The current study showed that PHI and %p2PSA were more powerful than the currently available markers with better predictive accuracy of RP pathological outcomes.
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![Receiver operating characteristic curve predicting the probability of (A) T3 at pathologic staging, (B) Gleason sum (GS) ≥7 at pathologic grading, and (C) GS upgrading. PSA, prostate specific antigen; fPSA, free PSA; p2PSA, \[−2\]proPSA; %p2PSA, percentage of p2PSA to tPSA; PHI, prostate health index.](icu-61-42-g002){#F2}

![Decision curve analysis of the effect of the prediction models. The net benefit is plotted against various threshold probabilities. (A) Detection of pT3 at radical prostatectomy. T-stage model 1 is a basic model that includes clinical stage, percentage of positive biopsy core, total prostate-specific antigen (tPSA), free PSA (fPSA), percent fPSA (%fPSA), biopsy Gleason sum (GS), and PSA density. T-stage model 2 is a basic model that includes all factors of model 1 plus a percentage of p2PSA to fPSA (%p2PSA). T stage model 3 is a basic model, which includes all factors of model 1 plus the Prostate Health Index (PHI). (B) Detection of pathologic GS ≥7 at radical prostatectomy. GS model 1 is a basic model that includes clinical stage, percentage of positive biopsy core, tPSA, and %fPSA. GS Model 2 is a basic model that includes all of the factors of model 1 plus %p2PSA. GS model 3 is a basic model that includes all of the factors of model 1 plus the PHI. (C) Detection of the presence of GS upgrading at radical prostatectomy. Upgrading model 1 is a basic model that includes clinical stage, percentage of positive biopsy core, tPSA, and %fPSA. Upgrading model 2 is a basic model that includes all of the factors of model 1 plus %p2PSA. Upgrading model 3 is a basic model that includes all of the factors of model 1 plus the PHI.](icu-61-42-g003){#F3}

###### Demographic and clinical characteristics of all study subjects
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  Variable                                     Value (n=160)
  -------------------------------------------- -------------------------
  Age (y)                                      68.4/69.7 (45--79)
  Clinical stage                               
   T1c                                         117 (73.1)
   ≥T2                                         43 (26.9)
  Prostate volume (mL)                         32.2/33.3 (12--96)
  tPSA (ng/mL)                                 11.7/7.7 (3.5--74.9)
  p2PSA                                        26.4/18.4 (0.7--189.6)
  %fPSA                                        0.14/0.12 (0.01--1.27)
  %p2PSA                                       1.92/1.69 (0.62--7.3)
  PSA density                                  0.28 (0.26)
  PHI                                          67.1/47.2 (19.5--360.9)
  Biopsy Gleason sum                           
   6                                           98 (61.3)
   7 (3+4)                                     20 (12.5)
   7 (4+3)                                     33 (20.6)
   ≥8                                          9 (5.6)
  Number of positive biopsy core               3.2/3 (1--12)
  Maximal percentage in each biopsy core (%)   45.2/39.5 (4.6--99.9)
  Pathology Gleason sum                        
   6                                           64 (40.0)
   7 (3+4)                                     50 (31.3)
   7 (4+3)                                     31 (19.4)
   ≥8                                          15 (9.4)
  Gleason upgrading                            34 (21.3)
  Tumor stage                                  
   T2                                          79 (49.4)
   T3a                                         76 (47.5)
   T3b                                         5 (3.1)
  Resection margin                             
   Negative                                    130 (81.3)
   Positive                                    30 (18.8)

Values are presented as mean/median (range), mean (median), or number (%).

PSA, prostate specific antigen; tPSA, total PSA; fPSA, free PSA; p2PSA, \[−2\]proPSA; %fPSA, percentage of fPSA to tPSA; %p2PSA, percentage of p2PSA to tPSA; PHI, prostate health index.

###### Univariate and multivariate analysis predicting the probability of pT3 by pathologic stage
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  Predictor                                  Univariate analysis   Multivariate analysis                                    
  ------------------------------------------ --------------------- ----------------------- -------------- ----------------- ----------------
  Age                                        0.428                 0.977; 0.289                                             
  Prostate volume                            0.496                 1.016; 0.093                                             
  Clinical stage                             0.653                 5.626; \<0.001          2.726; 0.273   2.734; 0.381      2.196; 0.451
  Percentage of positive biopsy core         0.598                 2.105; \<0.001          1.953; 0.083   1.879; 0.096      1.882; 0.085
  Biopsy Gleason sum                         0.753                 9.492; \<0.001          4.493; 0.002   1.952; 0.059      1.812; 0.061
  PSA density                                0.573                 2.291; \<0.001          1.156; 0.072   1.120; 0.125      1.156; 0.149
  tPSA                                       0.720                 1.162; \<0.001          1.157; 0.062   1.182; 0.045      1.142; 0.053
  fPSA                                       0.603                 1.135; 0.293                                             
  %fPSA                                      0.321                 0.001; \<0.001          0.089; 0.568   0.758; 0.883      0.074; 0.766
  p2PSA                                      0.774                 1.068; \<0.001                                           
  %p2PSA                                     0.850                 10.948; \<0.001                        13.145; \<0.001   
  PHI                                        0.913                 1.197; \<0.001                                           1.213; \<0.001
  AUC of multivariate models                                                               0.849          0.939             0.951
  Gain in predictive accuracy (%, p-value)                                                                9.0 (\<0.001)     10.2 (\<0.001)

AUC, area under the curve; OR, odds ratio; PHI, prostate health index; PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; %fPSA, the percentage of free PSA to total PSA; %p2PSA, the percentage of p2PSA to free PSA.

The AUC reflects the predictive values of individual variables (columns) and of the multivariate models in predicting the probability of pT3.

###### Univariate and multivariate analysis predicting the probability of Gleason sum ≥7 at pathologic staging
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  Predictors                                 Univariate analysis   Multivariate analysis                                       
  ------------------------------------------ --------------------- ----------------------- ----------------- ----------------- -------------------
  Age                                        0.445                 0.989; 0.623                                                
  Prostate volume                            0.491                 0.889; 0.723                                                
  Clinical stage                             0.698                 23.109; \<0.001         43.924; \<0.001   72.612; \<0.001   1982.218; \<0.001
  Percentage of positive biopsy core         0.637                 3.251; 0.021            7.421; \<0.001    14.861; \<0.001   22.176; \<0.001
  PSA density                                0.582                 1.023; 0.124                                                
  tPSA                                       0.714                 1.180; \<0.001          1.312; 0.038      1.612; 0.007      0.991; 0.968
  fPSA                                       0.570                 1.060; 0.611                                                
  %fPSA                                      0.287                 0.001; \<0.001          0.231; 0.845      8.239; 0.616      0.052; 0.790
  p2PSA                                      0.754                 1.063; \<0.001                                              
  %p2PSA                                     0.836                 10.557; \<0.001                                             
  PHI                                        0.849                 1.243; \<0.001                                              
  AUC of multivariate models                                                               0.861             0.901             0.932
  Gain in predictive accuracy (%, p-value)                                                                   4.0% (\<0.001)    7.1% (\<0.001)

AUC, area under the curve; OR, odds ratio; PHI, prostate health index; PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; %fPSA, the percentage of free PSA to total PSA; %p2PSA, the percentage of p2PSA to free PSA.

The AUC reflects the predictive values of individual variables (columns) and of the multivariate models for predicting the probability of Gleason sum ≥7.

###### Univariate and multivariate analyses predicting the probability of Gleason sum upgrading
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  Predictor                                  Univariate analysis   Multivariate analysis                                    
  ------------------------------------------ --------------------- ----------------------- -------------- ----------------- -----------------
  Age                                        0.480                 0.825; 0.842                                             
  Prostate volume                            0.510                 1.005; 0.924                                             
  Clinical stage                             0.583                 2.492; 0.031            1.852;0.139    1.153; 0.816      1.236; 0.773
  Percentage of positive biopsy core         0.602                 3.140; 0.025            1.125; 0.452   1.109; 0.529      1.298; 0.372
  PSA density                                0.559                 1.924; 0.093                                             
  tPSA                                       0.608                 1.082; \<0.001          0.976;0.583    0.911; 0.480      0.915; 0.036
  fPSA                                       0.541                 1.023; 0.506                                             
  %fPSA                                      0.392                 0.001; 0.019            0.001;0.046    0.001; 0.037      0.001; 0.041
  p2PSA                                      0.716                 0.001; 1.102                                             
  %p2PSA                                     0.726                 2.691; \<0.001                         2.716; \<0.001    
  PHI                                        0.749                 1.029; \<0.001                                           1.032; \<0.001
  AUC of multivariate models                                                               0.725          0.833             0.856
  Gain in predictive accuracy (%, p-value)                                                                10.8% (\<0.001)   13.1% (\<0.001)

AUC, area under the curve; OR, odds ratio; PHI, Prostate Health Index; PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; %fPSA, the percentage of free PSA to total PSA; %p2PSA, the percentage of p2PSA to free PSA.

The AUC reflects the predictive values of individual variables (columns) and of the multivariate models for predicting the probability of Gleason sum upgrading.

###### Sensitivity and specificity at three levels of prostate health index (high sensitivity, best combination, high specificity) for prediction of pT3 disease at pathology, Gleason sum ≥7, and Gleason sum upgrading
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  Prediction              Criterion            Sensitivity           Specificity           Positive predictive value   Negative predictive value
  ----------------------- -------------------- --------------------- --------------------- --------------------------- ---------------------------
  pT3 disease             ≥30.40               100.0 (95.5--100.0)   35.4 (25.0--47.0)     61.4 (52.5--69.7)           100.0 (87.7--100.0)
  ≥45.55                  93.8 (86.2--98.0)    91.1 (82.6--96.4)     91.6 (83.4--96.5)     93.5 (85.5--97.7)           
  ≥71.14                  45.7 (34.6--57.1)    100.0 (95.4--100.0)   100.0 (90.5--100.0)   64.2 (55.1--72.7)           
  Gleason sum ≥7          ≥22.29               100.0 (96.2--100.0)   7.81 (2.6--17.3)      61.9 (53.8--69.6)           100.0 (47.8--100.0)
  ≥45.55                  85.4 (76.7--91.8)    98.4 (91.6--100.0)    98.8 (93.5--100.0)    81.8 (71.4--89.7)           
  ≥49.93                  73.96 (64.0--82.4)   100.0 (94.4--100.0)   100.0 (94.9--100.0)   71.9 (61.4--80.9)           
  Gleason sum upgrading   ≥30.19               100.0 (94.3--100.0)   23.12 (17.2--36.2)    37.2 (30.9--49.3)           100.0 (86.1--100.0)
  ≥45.92                  91.2 (72.0--97.5)    66.3 (53.2--75.8)     58.1 (46.3--69.1)     94.2 (84.2--98.1)           
  ≥211.23                 6.54 (2.1--17.2)     100.0 (94.1--100.0)   100.0 (41.3--100.0)   70.2 (62.1--78.2)           

Values are presented as % (95% confidence interval).
